Gland Pharma Q2FY27 results: Net profit rises 58% to ₹290.75 crore
Gland Pharma set out an expansion in a quarterly results development for Q2FY27.
· BS Companies
Gland Pharma on Friday posted a 58.29 per cent rise in consolidated net profit to Rs 290.75 crore in the September quarter, driven by strong execution across businesses. The company had reported a net profit of Rs 183.68 crore in the year-ago period.
Key facts
- Period
- Q2FY27
The analysis
Gland Pharma reported ₹290.75 crore, Rs 183.68 crore and Rs 1,833.58 crore for Q2FY27, with movement of 58%, 31% and 58.29% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is +0.8% on the day at ₹3,169.30, and has returned +21.5% over three months. It is trading close to its 52-week high, so expectations were already elevated going in. The pharma & healthcare sector has moved +1.4% over the same period, so Gland Pharma is running 20.1 points ahead of its peers.
For Gland Pharma, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- In focus: Gland Pharma (GLAND), in Pharma & Healthcare.
- Over three months: Gland Pharma +21.5% against Pharma & Healthcare +1.4% (20.1 points ahead).
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| Gland PharmaGLAND · Pharma & Healthcare | ₹3,169.30 | +0.8% | +5.4% | +21.5% | 0.0% | 1.0× | — |
Pharma & Healthcare
1M +3.0% · 3M +1.4%
Gland Pharma
Prices as of 6 Nov 2026, 16:11 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Aster DM Quality Care Q2 net profit more than doubles to ₹262 crore
Q2 results, order win drive Symbiotec Pharma 20% higher to new high
Fortis Q2 net profit falls 2.5% on higher expenses, lower exceptional gain
Apollo's Bangladesh patient revenue nears pre-crisis peak of ₹450 crore
Glenmark Pharma Q2 revenue falls 30% to ₹4,247 crore, profit down 57%